We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
- Authors
DIAGO, M.; OLVEIRA, A.; SOLÁ, R.; ROMERO‐GÓMEZ, M.; MORENO‐OTERO, R.; PÉREZ, R.; SALMERÓN, J.; ENRÍQUEZ, J.; PLANAS, R.; GAVILÁN, J. C.; DEL OLMO, J.; URIBARRENA, R.; SILLERO, C.; BENÍTEZ, A.; SÁNCHEZ‐GALDÓN, S.; DALMAU, B.; ERAÑA, L.; MONTORO, M.; PORTU, J.; GARIJO, J. M.
- Abstract
Background Sustained virological response rates of up to 52% have been obtained with peginterferon α2a (40 kDa) plus ribavirin in patients suffering from chronic hepatitis C genotype 1 in randomized-controlled trials. Aim To assess early virological response and its clinical utility in predicting an sustained virological response in patients suffering from chronic hepatitis C genotype 1 in routine clinical practice in Spain. Methods Treatment-naïve patients received pegylated interferon α2a (40 kDa) 180 µg/week plus ribavirin 1000/1200 mg/day for 48 weeks, and were followed for a further 24 weeks. Overall, 475 patients received at least one dose of medication and were included in the efficacy population. Results The overall sustained virological response rate was 48%. Of those with week 12 virological data, 83% had an early virological response. The negative predictive value of an early virological response was 93%. Conclusion If sustained virological response is the goal, a treatment-decision based on a 12-week evaluation during routine clinical practice is feasible.
- Subjects
SPAIN; HEPATITIS C treatment; RIBAVIRIN; DRUG dosage; MEDICAL virology
- Publication
Alimentary Pharmacology & Therapeutics, 2007, Vol 25, Issue 8, p899
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2007.03270.x